ArticleWorld journal of clinical cases2025
Liver function improvement after human placental extract injections in patients with chronic liver disease: Thirty case reports.
Article in World journal of clinical cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Revitalizing liver health: Human placental extract shows promise in chronic liver disease management.World journal of clinical cases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis case report describes a protocol developed by Danaun Medical Clinic for the introduction of a pioneering intervention comprising intravenous human placental extract (HPE) therapy to improve the liver function of patients with chronic liver disease (CLD). CASE SUMMARY: This study involved data from patients whose chief complaint was reduced quality of life attributable to CLD. The new treatment approach resulted in improvements in the liver function and fatty liver of 30 patients with CLD. Improvements were observed using abdominal ultrasonography. Unlike traditional methods, this protocol provided more sustainable and meaningful results. Treatment with 10 mL of HPE administered intravenously once or twice per week significantly improved liver function. The observed improvements in fatty liver and liver function suggest the utility of this approach for the management of patients with CLD.
conclusionThis case series highlights the potential of innovative treatments for patients with CLD that could improve the quality of life of the patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.